Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00896454 · ClinicalTrials.gov registry record · Phase 2
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT00896454 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 33 participants.
The verdict
NCT00896454, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the potential of denosumab to treat Hypercalcemia of Malignancy in patients with elevated serum calcium who do not respond to recent treatment with intravenous bisphosphonates by lowering corrected serum calcium \</= 11.5 mg/dL (2.9 millimoles /L) by day 10.
Interventions
- DRUG denosumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2009-11-16 |
| Est. Completion | 2013-08-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00896454
The ClinicalTrials.gov registry entry for NCT00896454 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which denosumab is the first listed.
NCT00896454 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00896454 about?
NCT00896454 is a clinical study titled "Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium". The purpose of this study is to determine the potential of denosumab to treat Hypercalcemia of Malignancy in patients with elevated serum calcium who do not respond to recent treatment with intravenous bisphosphonates by lowering corrected serum calcium \</= 11.5 mg/dL (2.9 millimoles /L) by day 10.
What is the current status of trial NCT00896454?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2009-11-16. Estimated completion is 2013-08-21.
What interventions are being tested in trial NCT00896454?
The interventions under investigation include: denosumab (DRUG).
Who is sponsoring clinical trial NCT00896454?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.